期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

前列腺癌生物标志物筛查的临床研究现状 被引量：6

Present status of clinical researches on the screening for prostate cancer biomarkers
原文传递
导出
摘要 肿瘤的生物标志物研究对肿瘤的早期诊断和治疗有重要意义。虽然前列腺特异性抗原(PSA)用于临床前列腺癌的筛查和治疗效果评价已经20余年,但是其效果并不能完全让人满意。随着对前列腺癌研究的深入,目前已经发现了多种前列腺癌的生物标志物。本文就前列腺癌生物标志物筛查的临床研究进展进行综述。 Researches on the biomarkers of tumors are very important for their early diagnosis and treatment.Although PSA has been used for over 20 years for screening prostate cancer and evaluating its treatment,the results are not entirely satisfactory.With the deepening of the researches on prostate cancer,a variety of prostate cancer biomarkers have been found.This article presents an overview on the recent advances in the screening for prostate cancer biomarkers.
作者 何跃 秦国东 肖明朝
机构地区 重庆医科大学附属第一医院泌尿外科
出处 《中华男科学杂志》 CAS CSCD 北大核心 2011年第11期1029-1032,共4页 National Journal of Andrology
关键词 生物标志物 筛查 前列腺癌 biomarker screen prostate cancer
分类号 R737.25 [医药卫生—肿瘤]
  • 相关文献

参考文献4

二级参考文献52

  • 1Mhawech-Fauceglia P,Zhang S,Terracciano L,黄文斌（摘译）.前列腺特异性膜抗原蛋白在正常和肿瘤组织中的表达及其在前列腺癌诊断中的敏感性和特异性[J].临床与实验病理学杂志,2007,23(3):261-261. 被引量：35
  • 2Thompson IM, Pauler DK, Goodman P J, et al. Prevalence of prostate cancer among men with a prostatespecific antigen level <or =4.0 ng per milliliter [J]. N Engl J Med, 2004, 350 ( 22 ) : 2239 -2246.
  • 3Stamey TA, Johnstone IM, McNeal JE, et al. Preoperative serum prostate specific antigen levels between 2 and 22 ng/mL correlate poorly with postradical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng/mL [J]. J Urol, 2002, 167 (1):103-111.
  • 4Scattoni V, Zlotta A, Montironi R, et al. Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature [J]. Eur Urol, 2007,52(5) : 1309-1322.
  • 5Roddam AW, Duffy M J, Hamdy FC, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/mL: systematic review and meta-analysis [J]. Eur Urol, 2005,48(3) : 386-399.
  • 6Bratslavsky G, Fisher HA, Kaufman RP Jr, et al. PSA-related markers in the detection of prostate cancer and high-grade disease in the contemporary era with extended biopsy [J]. Urol Oncol, 2008,26(2) : 166-170.
  • 7Sokoll LJ, Wang Y, Feng Z, et al.[-2] proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study [J]. J Urol, 2008,180(2) :539-543.
  • 8Fitzpatrick JM, Banu E, Oudard S. Prostate-specific antigen kinetics in localized and advanced prostate cancer [J]. BJU Int, 2009,103(5):57S-587.
  • 9Carpten J, Nupponen N, Isaacs S, et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1 [J]. Nat Genet, 2002,30(2) : 181-184.
  • 10Rokman A, Ikonen T, Seppala EH, et al. Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer [J]. Am J Hum Genet, 2002,70(5) : 1299-1304.

共引文献17

同被引文献124

  • 1吴琪俊,徐剑锋,施榕.前列腺癌易感基因及遗传流行病学研究进展[J].上海交通大学学报（医学版）,2011,31(5):672-675. 被引量：10
  • 2叶定伟.前列腺癌的流行病学和中国的发病趋势[J].中华外科杂志,2006,44(6):362-364. 被引量：170
  • 3Shariat SF, Seherr DS, Gupta A, et al. Emerging biomarkers for prostate cancer diagnosis, staging, and prognosis. Arch Esp Urol, 2011, 64(8): 681-694.
  • 4Raziuddin A, Court D, Sarkar FH, et al. A c-erbB-2 promoter-specific nuclear matrix protein from human tumor tissues meiates NF-KappaB DNA binding activity. J Biol Chem, 1997, 272 (25) : 15715-15720.
  • 5Cazares LH, Drake RR, Esquela-Kirscher A, et al. Molecular pathology of prostate cancer. Cancer Biomark, 2011, 9 ( 1-6 ): 441-459.
  • 6Tosoian J, Loeb S. PSA and beyond : The past, present, and future of investigative biomarkers for prostate cancer. Scientific World Journal, 2010, 10: 1919-1931.
  • 7Stamey TA. Preoperation serum prostate-specific antigen (PSA) below 10 μg/L predicats neither the presence of prostate cancer nor the rate of post operation PSA failure. Clin Chem, 2001,47 (4) : 631-634.
  • 8Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate specific antigen level < or = 4.0 ng/ml per milliliter. N Engl J Med, 2004, 350 (22): 2239-2246.
  • 9Kumar A, Kumar R, Gupta NP. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer. Jpn J Clin Oncol, 2006, 36(3) : 172-175.
  • 10Lau P, Chin JL, Pautler S, et al. NMP22 is predictive of recurrence in high-risk superficial bladder cancer patients. Can Urol Assoe J, 2009, 3(6) : 454-458.

引证文献6

二级引证文献19

中华男科学杂志
2011年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部